From the Research
Botropase is not a botulinum antitoxin but rather a hemostatic agent containing batroxobin (hemocoagulase), and its recommended dosage for bleeding control is typically 1-2 mL (20-40 KU) administered intramuscularly or intravenously, given 1-3 times daily depending on the severity of bleeding. The most relevant study for this question is 1, which evaluated the effects of botropase on various clotting factors in human volunteers.
- The study found that botropase significantly reduced the plasma level of fibrinogen and fibrin degradation products after 5 min of IV administration.
- It also observed that factor X was reduced constantly by botropase administration, suggesting enhanced turnover between 5 and 20 min of IV administration.
- Although botropase reduced clotting and bleeding time in all the volunteers, the data remains to be statistically insignificant. For severe bleeding, the intravenous route is preferred for faster action.
- Treatment duration usually ranges from 3-7 days based on clinical response.
- When administering intravenously, it should be given slowly over 5-10 minutes to avoid adverse reactions. Botropase works by converting fibrinogen to fibrin and promoting blood clotting at the site of bleeding.
- It's essential to note that Botropase is contraindicated in patients with hypersensitivity to snake venom derivatives, disseminated intravascular coagulation (DIC), or severe liver disease.
- Monitor the patient for signs of hypersensitivity reactions during administration, especially with the first dose. Other studies, such as 2, 3, 4, and 5, provide information on the use of antifibrinolytic agents, such as tranexamic acid, in various clinical settings, but they are not directly relevant to the dosage calculation of Inj Botropase.